New therapeutic target expands options for multiple myeloma

In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, and produced a median duration of response of 11.2 months before the cancer progressed.

Raccontata damedicalxpress.com